李龙承(Long-Cheng LI)李龙承 特聘教授/研究员

Tel: 010-69156281 (办)
Email: lilongcheng {at} pumch.ac.cn

中国医学科学院北京协和医院分子医学研究室 教授/研究员 博士生导师
北京协和医院中心实验室 主任, 实验动物中心 主任(兼)
北京协和医院实验动物管理委员会 主任委员

研究领域

      非编码RNA与基因调控、RNA激活、肿瘤表观遗传、泌尿系肿瘤

实验室网站

简      介

      1984年和1991年分别获得同济医科大学医学学士和外科学硕士学位,2004年获得华中科技大学临床医学博士学位。 1998年至2000年在美国加州大学旧金山分校(UCSF)从事博士后研究。2007年成为UCSF助理教授,2011年成为副教授(终身制)。国家海外杰出青年基金获得者。2014年1月回国工作。先后获得美国NIH历史上第一次(2009年)设立的鼓励高风险创新性计划—NIH主任Transformative R01基金、NIH R21、美国国防部前列腺癌基金及美国AACR膀胱癌基金。获得三项美国专利,专利许可已转让给英国Mina Therapeutics公司。该公司开发的国际上第一个基于RNAa的药于2016年进入临床试验用于肝癌治疗。 

       现担任《中华医学杂志》 (英文版)编委,为《PNAS》、《Nature Communications》、《Nature Chem Biol》等30多种期刊的审稿人。为美国NIH主任特别基金、美国国防部前列腺癌研究计划、英国前列腺癌慈善基金会、意大利卫生部、国家自然科学基金重点项目评审人。曾多次应邀到各种国际学术会议、大学和工业界进行专题演讲。如American College of Medical Genetics (ACMG) 2008年年会、Oligonucleotide Therapeutics Society第六届年会、韩国Society for Microbiology and Biotechnology 2011年年会、第四届 RNAi Research & Therapeutics会议,美国Fox Chase癌症中心、南佛罗里达大学生物系、Duquesne大学、辛辛那提大学、Sigma公司、Alnylam制药公司、Sirna制药公司、Genentech生物科技公司等。为著名的生物医学研究资讯网站“Protocol Online”及DNA甲基化分析在线软件“MethPrimer”的作者。

       主要研究方向为小非编码RNA与表观遗传。在国际学术期刊发表相关论文70余篇,总引用次数达7500余次,H指数为42(根据Google Scholar数据)。

荣誉和奖励
1997            Société Internationale d'Urologie Fellowship
2008            国家自然基金海外杰出青年基金
2009            NIH Director’s Transformative Research Award
 

发表文章

英文论文(* 通讯作者)

  1. Li LC*, Zhang YS, Hu RZ, Zhou XC: Inhibitory effect of fluoride on renal stone formation in rats. Urologia Internationalis 1992;48:336-41.
  2. Li LC*, Zhang Y, Lin Q, Li C, He M: Clinical application of monoclonal antibody-drug conjugate to immunotargeting chemotherapy of bladder cancer. Chin Med J (Engl) 1995 Oct;108(10):764-8.
  3. Li LC*, Zhang X, Zhou SW, Zhou XC, Yang WM, Zhang YS: Experience with repair of hypospadias using bladder mucosa in adolescents and adults. J Urol. 1995 Apr;153(4):1117-9.
  4. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int J Cancer 1999 Nov 26;83(5):610-4.
  5. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R: Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000 Feb 1;60(3):702-6.
  6. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll PR, Dahiya R: A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000 Feb 15;60(4):873-6.
  7. Li LC, Yeh CC, Nojima D, Dahiya R. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun. 2000 Aug 28;275(2):682-9.
  8. Nojima D, Nakajima K, Li LC, Franks J, Ribeiro-Filho L, Ishii N, Dahiya R. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001 Sep;32(1):19-27.
  9. Dasari VK, Goharderakhshan RZ, Perinchery G, Li LC, Tanaka Y, Alonzo J, Dahiya R. Expression analysis of Y chromosome genes in human prostate cancer. J Urol. 2001 Apr;165(4):1335-41.
  10. Li LC, Zhao H, Nakajima K, Oh BR, Filho LA, Carroll PR, Dahiya R.  Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 2001 Aug;166(2):705-9.
  11. Nojima D, Li LC, Dharia A, Perinchery G, Ribeiro-Filho L, Yen TB and Dahiya R. CpG Hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 2001 Oct 15; 92(8):2076-83.
  12. Nojima D, Nakajima K, Li LC, Franks J, Ribeiro-Filho L, Ishii N, Dahiya R. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog. 2001 Sep;32(1):19-27.
  13. Zhao H, Patra A, Tanaka Y, Li LC, Dahiya R. Transforming growth factor-beta(s) and their receptors in aging rat prostate. Biochem Biophys Res Commun. 2002 Jun 7; 294(2):464-9.
  14. Li LC and Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; Nov; 18(11):1427-31.
  15. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog. 2002 Aug; 34(4):187-98.
  16. Li LC, Zhao H, Shiina H, Kane CJ and Dahiya R.  PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res 2003, Jan 1;31(1):291-3.
  17. Zhao H, Patra A, Tanaka Y, Li LC, Dahiya R. Transforming growth factor-betas and their receptors in aging rat prostate. Biochem Biophys Res Commun 2002 Jun 7;294(2):464-9.
  18. Zhang X, Ye ZQ, Chen Z, Chen ZQ, Zhu QG, Xin M, Li LC. Comparison of open surgery versus retroperitoneoscopic approach to chyluria. J Urol. 2003 Mar; 169(3):991-3.
  19. Zhang X, Ma X, Chen Z, Li LC and Ye ZQ. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of urinary bladder. J Urol 2003 Oct;170(4 Pt 1):1379-82.
  20. Li LC, Okino ST and Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 2004 Sep 20;1704(2):87-102.
  21. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll PR, Igawa M and Dahiya R. Age-dependent methylation of estrogen receptor alpha in prostate cancer. Biochem Biophys Res Commun 2004 Aug; 20 321(2):455-461.
  22. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004 Sep 1; 64(17):5956-62.
  23. Zhao H, Li LC, Okino ST, Kane CJ, Carroll PR, Dahiya R. Kidney gene database: a curated and integrated database of genes involved in kidney diseases. J Urol. 2004 Dec;172(6 Pt 1):2344-6.
  24. Li LC, Carroll PR, and Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005 Jan 19;97(2):103-15.
  25. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005 Feb 1;11(3):1028-36.
  26. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 2005 Mar 15;65(6):2130-8.
  27. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005 Aug 20;116(2):174-81.
  28. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005 Jul 1;104(1):44-52.
  29. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005 Aug 15;11(16):5793-801.
  30. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005 Sep 15;11(18):6582-8.
  31. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006 Jan 1;106(1):79-86. 
  32. Pokot D, Li LC*, Enokida H, Tabatabai ZL, Kane CJ, Carroll P, and Dahiya R. The E-cadherin -160 C/A polymorphism can predict higher risk for race-related prostate cancer. J Urol 2006 Aug;176(2):793-6.
  33. Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res. 2006 Aug 1; 66(15):7420-8.
  34. Li LC*, Okino ST, Zhao H, Pokot D, Place RF, Dahiya R*. Small double-stranded RNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA. 2006 Nov 14;103(46):17337-17342.
  35. Okino ST, Pookot D, Majid S, Zhao H, Li LC, Place RF, Dahiya R. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol Carcinog. 2007 Oct;46(10):839-46.
  36. Li LC* and Dahiya R. Epigenetics of prostate cancer. Frontiers in Bioscience 2007 May 1;12,3377-3397.
  37. Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, Li LC, Dahiya R. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun. 2007 Mar 23;354(4):852-7. Epub 2007 Jan 9.
  38. Li LC*. Designing PCR primer for DNA methylation mapping. Methods Mol Biol. 2007; 402:371-84.
  39. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13. Epub 2008 Jan 28.
  40. Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC*. Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells. Mol Cancer Ther. 2008 Mar;7(3):698-703.
  41. Li LC*. The multifaceted small RNAs. RNA Biol. 2008 Apr-Jun;5(2):61-4. Epub 2008 Mar 29.
  42. Yan TZ, Jin FS, Xie LP, Li LC. Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer. Urol Int. 2008;81(2):228-33. Epub 2008 Aug 29.
  43. Ning H, Liu G, Lin G, Garcia M, Li LC, Lue TF, Lin CS. Identification of an aberrant cell line among human adipose tissue-derived stem cell isolates. Differentiation 2009 Feb;77(2):172-80. Epub 2008 Oct 21.
  44. Dharap A, Bowen K, Place R, Li LC, Vemuganti R. Transient focal ischemia induces extensive temporal changes in rat cerebral MicroRNAome. J Cereb Blood Flow Metab. 2009 Apr;29(4):675-87.
  45. Ning H, Huang YC, Banie L, Hung S, Lin G, Li LC, Lue TF, Lin CS. MicroRNA regulation of neuron-like differentiation of adipose tissue-derived stem cells. Differentiation. 2009 Aug 18. [Epub ahead of print]
  46. Lin G, Yang R, Banie L, Wang G, Ning H, Li LC, Lue TF, Lin CS. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate. 2010 Mar 15. [Epub ahead of print]
  47. Huang V, Qin Y, Wang J, Wang X, Place RF, Lin GT, Lue TF, Li LC*. RNAa is conserved in mammalian cells. PLoS ONE. 2010 5(1): e8848. doi:10.1371/journal.pone.0008848.
  48. Place RF, Noonan EJ, Foldes-Papp Z and Li LC*. Defining features and exploring chemical medications to manipulate RNAa activityCurrent Pharm Biotech 2010 Aug;11(5):518-26.
  49. Noonan EJ, Place RF, Basak S, Pookot D, Li LC*. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. OncoTarget 2010 Sep 13;1(5):349-358.
  50. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J, and Li LC*. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res. 2010;70:10182-10191.
  51. Portnoy V, Huang V, Place RF and Li, LC*. Small RNA and transcriptional upregulation. WIREs RNA 2011 Sep-Oct; 2(5):748-60..
  52. Huang V, Place RF,Portnoy V, Wang J, Qi Z, Jia Z, Yu A, Shuman M, Yu J, Li LC*. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012 Feb; 40(4):1695-707.
  53. Wang J, Li LC*. Small RNA and its application in andrology and urology. Transl Androl Urol 2012; 1(1):33-43.
  54. Huang V and Li LC*. miRNA goes nuclear. RNA Biology 2012 Mar 1;9(3).
  55. Place RF, Wang J, Noonan E, Meyers R, Manoharan M, Charisse K, Duncan R, Huang V, Wang X and Li LC*. Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Molecular Therapy - Nucleic Acids 2012; e15.
  56. Wang X, Wang J, Huang V, Place RF, and Li LC*. Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation. Biochem J 2012 May 1; 443(3):821-8.
  57. Kang MR, Yang G, Charisse K, Epstein-Barash H, Manoharan H and LI LC*. An orthotopic bladder tumor model and the evaluation of intravesical saRNA treatment. J Vis Exp. 012;(65), e4207.
  58. Kosaka M, Kang MR, Yang G and Li LC*. Targeted p21 WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells. Nucleic Acid Ther 2012 2012 Oct; 22(5):335-43.
  59. Kang MR, Yang G, Place RF, Charisse K, Epstein-Barash H, Manoharan H and LI LC*. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res 2012 Oct 1;72(19):5069-79.  
  60. Ahmed M, Li LC*. Adaptation and clonal selection models of castration resistant prostate cancer: current perspective. Int J Urol 2013 Apr; 20(4):362-71.
  61. Wang T, Li M, Yuan H, Zhan Y, Xu H, Wang S, Yang W, Liu J and Li LC. Small activating RNA-guided iNOS up-regulation improves erectile function of diabetic rats. J Urol 2013 Aug; 190(2):790-8.
  62. Ren S, Kang MR, Wang J, Huang V, Place RF, Sun Y*, Li LC*. Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth. Prostate 2013 Oct; 73(14):1591-601.
  63. Huang V, Zheng J, Qi Z, Wang J, Place RF, Yu J, Li H*, Li LC*. Ago1 Interacts with RNA Polymerase II and Binds to the Promoters of Actively Transcribed Genes in Human Cancer Cells. PLoS Genet 2013 Sep; 9(9):e1003821.
  64. Li LC*. Chromatin remodeling by the small RNA machinery in mammalian cells. Epigenetics. 2014 Jan 1; 9(1):45-52.
  65. Jiao L, Deng Z, Xu C, Yu Y, Li Y, Yang C, Chen J, Liu Z, Huang G, Li LC*, Sun Y*. MicroRNA-663 Induces Castration-Resistant Prostate Cancer Transformation and Predicts Clinical Recurrence. J Cell Physiol 2014 Jul; 229(7):834-44.
  66. Huang V, Li LC*. Demystifying the nuclear function of Argonaute proteins. RNA Biol 2014 Jan 1; 11(1):18-24.
  67. Li LC*, Gruenert DC*. Scientific methods – the foundation of science. J Biol Methods 2014;1(1):e4. doi: 10.14440/jbm.2014.20
  68. Li G, Pan T, Guo D, Li LC*. Regulatory Variants and Disease: The E-Cadherin −160C/A SNP as an Example. Mol Biol Intl 2014; 2014:967565.
  69. Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC. Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS Lett 2014 Nov 11.
  70. Guo D, Barry L, Lin S, Huang V, Li LCRNAa in action: from the exception to the norm. RNA Biology 2014;11(10):1221-5. doi: 10.4161/15476286.2014.972853..
  71. Wang J, Huang V, Ye L, Bárcena A, Lin G, Lue TF and Li LC* Identification of small activating RNAs that enhance endogenous OCT4 expression in human mesenchymal stem cells. Stem Cell Dev 2014 Sep 18. [Epub ahead of print].
  72. Wang J, Place RF, Portnoy V, Huang V, Kang MR, Kosaka M, Ho MK, Li LC* Inducing gene expression by targeting promoter sequences using small activating RNAs. J Biol Methods. 2015 Mar 11; 2(1).
  73. Portnoy V, Lin SH, Li KH, Burlingame A, Hu ZH, Li H, Li LC*. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016 Feb 23. doi: 10.1038/cr.2016.22. [Epub ahead of print]
  74. Li C, Jiang W, Hu Q, Li LC, Dong L, Chen R, Zhang Y, Tang Y, Thrasher JB, Liu CB, Li B. Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis. Oncotarget. 2016 Mar 23. doi: 10.18632/oncotarget.8290.
  75. Jin X, Ma J, Liang X, Tang K, Liu Y, Yin X, Zhang Y, Zhang H, Xu P, Chen D, Zhang T, Lu J, Hu Z, Qin X, Zeng X, Li L, Huang B. Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway. Biomaterials. 2017 Jan;113:93-104

中文论文

  1. 李龙承,周四维,叶章群,庄乾元,李家贵 12肋缘上切口在肾及肾上腺手术中的应用 临床泌尿外科杂志 1998; 05. 
  2. 李龙承, 章咏裳 氟化物饮水对大鼠肾结石形成的影响 中华泌尿外科杂志 1992; 13
  3. 李龙承, 章咏裳 膀胱小细胞癌 中华泌尿外科杂志1991;12:231.
  4. 陈忠, 李龙承* 肿瘤表观遗传研究的现状与展望 现代泌尿生殖肿瘤杂志, 2010,2(4):193-195.
  5. 陈忠*, 李龙承 RNAa 与肿瘤. 现代泌尿生殖肿瘤杂志, 2009, 1(1):1-3.
  6. 郭丹, 李龙承*从人到线虫的RNAa现象 科学通报 2014, 59: 2918–2925

其他创造性工作

  1. MethPrimer: a program for designing primers for methylation PCR such as bisulfite sequencing PCR, methylation specific PCR (MSP) at http://www.urogene.org/methprimer (2002) 
  2. PGDB: Prostate Gene Database at http://www.urogene.org/pgdb (2003)
  3. KGDB: Kidney Gene Database at http://www.urogene.org/kgdb (2004)
  4. Protocol Online: a database of research protocols and methods at http://www.protocol-online.org (1999)

    

  1. Li LC and Dahiya R. (2005) Small activating RNA molecules and methods of use. US patent 8,877,721,PCT International Application No. PCT/US06/13559.
  2. Place R, Li LC. (2010) Modified small activating RNA molecules and methods of use. US patent 9,045,751.
  3. Li LC. (2010) NKX3-1 saRNA and KLF4 saRNA and uses thereof. US patent 9,045,752. International Application Number: PCT/US11/27587.
  4. Place R, Li LC and Dahiya R. (2008) Methods of increasing gene expression. US patent pending 61/023,793. PCT/US08/88243, JAPAN Patent Application No. 2010-540877.
  5. Li LC. (2010) Methods and Compositions for Generation of Induced Pluripotent Stem Cells by RNAa. US patent pending 61/377,259.
  6. 一种小激活RNA及其制备方法和应用(中国专利申请号:201510115335.2,国际申请号:PCT/CN2015/074358)

    

  1. Li LC (2008) “Small RNA-mediated gene activation”: RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Ed. Morris KV. Caister Academic Press Norfolk, UK, pp 189-199.
  2. Greene KL, Li LC, Okino ST and Carroll PR (2008) “Molecular Basis of Prostate Cancer”: The Molecular Basis of Cancer. Ed. Mendelsohn J et al. Saunders, Philadelphia, PA, pp 431-440.
  3. Noonan EJ, Place RF and Li LC (2011) “MicroRNAs in predicting radiotherapy and chemotherapy response”: MicroRNAs in Cancer Translational Research. Ed. Cho WCS, Springer Science. pp 415-447
  4. Li LC (2007)“Design PCR primer for DNA methylation mapping” in Yuryev A. (ed) PCR primer design: Methods in Molecular Biology. Humana Press, Totowa, New Jersey, USA.  pp370-383.
  5. Li LC, Hsieh AC, Rugger D, Greene KL and Carroll PR. (2014) "Molecular Basis of Prostate Cancer": The Molecular Basis of Cancer (4th Edition). Ed. Mendelsohn J et al. Saunders, Philadelphia, PA pp 549-560.

    

  1. 李龙承, 张旭 主译 《泌尿外科手术图谱》 人民卫生出版社, 1996年

媒体报道及评论

  1. 我科学家证实细胞内小RNA分子具有基因激活功能 新华社 2006年11月9日
  2. Small RNAs reveal an activating side. Ken Garber, Science, 2006 Nov 3;313:741-42.
  3. E-Cadherin SNP linked to prostate cancer in White patients. MedWire News 28 July 2006.
  4. How to get your genes switched on. New Scientist, 2006 Nov 18:20.
  5. Activating gene expression. Elizabeth M. Science. STKE, 2006 Nov 21;362:392.
  6. Positive Interferenz. Sascha Karberg, Süddeutsche Zeitung, 2006 Nov 8.
  7. Transcriptional activation by small RNA duplexes. John Rossi, Nature Chemical Biology, 2007 March;3(3):136-37.
  8. Switched on. Bob Holmes, New Scientist, 2007 April 7:42-45.
  9. Scientists' new genes discovery may be manipulated to disable any disease. Sam Ejike Okoye, Guardian 2007 Jul 5.
  10. Hitting the on switch, Erika Check, Nature, 2007 Aug 23;448:885-58.
  11. Now showing: RNA Activation. Elie Dolgin, The Scientist 2009;23(5):34-39.
  12. Intravesical RNA activation—a new treatment concept. Sarah Payton, Nature Reviews Urology  28 August 2012; doi:10.1038/nrurol.2012.173
  13. MiNA Completes Exclusive License Agreement with University of California San Francisco to license RNAa patents. Businesswire November 18, 2014
  14. Perspectives on current science – June 2016. Oligonucleotide Therapeutics Society  http://www.oligotherapeutics.org/transcriptional-activation-by-sarnas-a-mechanism-distinct-from-rnai/
  15. MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer. Businesswire June 2, 2016